RxDoctor Payments Data

Julia Ro, PA

Physician Assistant · New York, NYNPI 1912390428

Payments from drug & device makers

$14,373in general payments, 2019–2025

Across 759 payments — averaging $18.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Dermavant Sciences, Inc.$1K
  • Lilly USA, LLC$1K
  • Johnson & Johnson$1K
  • UCB, Inc.$1K
  • E.r. Squibb & Sons, L.L.C.$830
  • plus $6K from 23 others

What the payments were for

  • Food & beverage$14,06798%
  • Education$3062%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,373 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$34,818
Medicare patients
133
Services billed
501

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Taltz AutoinjectorIxekizumab14$99,333
Dupixent PenDupilumab19$68,297
OtezlaApremilast12$54,281
JubliaEfinaconazole15$13,639
ZoryveRoflumilast13$10,706
Tacrolimus15$3,642
Fluocinonide74$3,430
Ketoconazole151$3,204
Clobetasol Propionate41$3,074
Tretinoin37$2,957
Clindamycin Phosphate41$1,395
Triamcinolone Acetonide130$988
Ciclopirox11$735
Betamethasone Dipropionate16$651
Fluocinolone Acetonide15$424

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$114$54,28112 claims
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$623$13,63915 claims
Arcutis Biotherapeutics, Inc.Zoryve$570$10,70613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →